4D Molecular Therapeutics Inc
NASDAQ:FDMT
4D Molecular Therapeutics Inc
Revenue
4D Molecular Therapeutics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
Revenue
$20.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
4D Molecular Therapeutics Inc
Revenue Breakdown
Breakdown by Geography
4D Molecular Therapeutics Inc
Total Revenue:
20.7m
USD
|
United States:
20.2m
USD
|
Netherlands:
567k
USD
|
Breakdown by Segments
4D Molecular Therapeutics Inc
Total Revenue:
20.7m
USD
|
Collaboration And License Revenue:
20m
USD
|
See Also
What is 4D Molecular Therapeutics Inc's Revenue?
Revenue
20.7m
USD
Based on the financial report for Dec 31, 2023, 4D Molecular Therapeutics Inc's Revenue amounts to 20.7m USD.
What is 4D Molecular Therapeutics Inc's Revenue growth rate?
Revenue CAGR 5Y
8%
Over the last year, the Revenue growth was 562%. The average annual Revenue growth rates for 4D Molecular Therapeutics Inc have been 15% over the past three years , 8% over the past five years .